Takayuki Katayama - Santen Pharmaceutical Independent Director
| SNPHY Stock | USD 9.23 0.20 2.12% |
Director
Mr. Takayuki Katayama was serving as Independent Director in Santen Pharmaceutical Co., Ltd. since June 2012. He is also serving as Independent Director in Olympus Corporationrationration, and working for Teijin Limited. He used to work for Toyo Seikan Group Holdings, Ltd. since 2012.
| Age | 72 |
| Tenure | 12 years |
| Phone | 81 6 7664 8621 |
| Web | https://www.santen.com |
Santen Pharmaceutical Management Efficiency
Santen Pharmaceutical's management efficiency ratios could be used to measure how well Santen Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jose Gras | Grifols SA ADR | N/A | |
| Bernard Poussot | Roche Holding Ltd | 66 | |
| Brett Ingersoll | Grifols SA ADR | N/A | |
| Antonio Pares | Grifols SA ADR | N/A | |
| Marla Salmon | Grifols SA ADR | N/A | |
| Anita Hauser | Roche Holding Ltd | 49 | |
| Peter Voser | Roche Holding Ltd | 59 | |
| John Bell | Roche Holding Ltd | 65 | |
| Tomas Gelabert | Grifols SA ADR | N/A | |
| Claudia Dyckerhoff | Roche Holding Ltd | 51 | |
| Inigo Mardones | Grifols SA ADR | N/A | |
| Richard Lifton | Roche Holding Ltd | 65 | |
| Christoph Franz | Roche Holding Ltd | 58 | |
| Beatrice Mauro | Roche Holding Ltd | 49 | |
| Anna Lluch | Grifols SA ADR | N/A | |
| Pius Baschera | Roche Holding Ltd | 65 | |
| DeAnne Julius | Roche Holding Ltd | 66 | |
| Julie Brown | Roche Holding Ltd | 56 | |
| Belen Morenes | Grifols SA ADR | 45 | |
| Mateo Humbert | Grifols SA ADR | 68 | |
| Luis Bobadilla | Grifols SA ADR | N/A | |
Management Performance
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 |
Santen Pharmaceutical Leadership Team
Elected by the shareholders, the Santen Pharmaceutical's board of directors comprises two types of representatives: Santen Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santen. The board's role is to monitor Santen Pharmaceutical's management team and ensure that shareholders' interests are well served. Santen Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santen Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Satoshi Suzuki, Executive Officer, Chief Director of Planning | ||
| Kanoko Ohishi, Independent Director | ||
| Nikolas Tripodis, Chief Officer | ||
| Noriaki Yamamoto, CIO, Head of Information Systems Division and Corporate Officer | ||
| Akira Kurokawa, CEO and President Director, Member of Nominating Committee, Member of Executive Compensation Committee and Member of Corporate Strategy Committee | ||
| Hidetaka Mizutani, Manager of Finance & Accounting Group | ||
| Kenji Morishima, Executive Officer, Chief Director of Human Resources & Organization Development and CSR | ||
| Nobuko Kato, Chief Officer | ||
| Sadatoshi Furukado, Senior Managing Executive Officer, Director of Medical Business, Director | ||
| Ken Araki, Executive Officer, Senior Director of Global Business Development | ||
| Mika Masunari, G Officer | ||
| Masamichi Sato, Head of CSR and General Affairs Division and Sr. Corporate Officer of Corporate Devel. | ||
| Kazuo Koshiji, CFO, Head of Fin. Division and Sr. Corporate Officer | ||
| Kaori Itagaki, Gen Group | ||
| Akihiro Tsujimura, Executive Officer, Director of Asia Business | ||
| Takeshi Ito, Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit | ||
| Shinichi Teramachi, Head Officer | ||
| Frank Binder, Executive Officer, Chief Director of Supply Chain | ||
| Ippei Kurihara, Japan Department | ||
| Yutaro Shintaku, Independent Director | ||
| Akihiro Okumura, Independent Director | ||
| Yutaro Shinta, Independent Director | ||
| Jyrki Liljeroos, Executive Officer and Presidentident of Subsidiary | ||
| Shiro Hatagami, Manager of Finance & Accounting Group | ||
| Keizo Nakada, Executive Officer, Chief Director of Product Supply | ||
| Ko Takahashi, Executive Officer | ||
| Akio Kimura, Executive Officer, Chief Director of Reliability Guarantee | ||
| Miki Fujima, Executive Officer, Chief Director of Human Resources | ||
| Naveed Shams, Chief Scientific Officer, Executive Officer and Presidentident and CEO of Subsidiary | ||
| Atsutoshi Ohta, Executive Officer, Chief Director of Production & Logistics | ||
| Hiroyuki Yamazaki, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit | ||
| Takahiro Morita, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit | ||
| Ye Liu, Executive Officer, General Manager of Subsidiary | ||
| Takayuki Katayama, Independent Director | ||
| Luis Iglesias, Executive Officer | ||
| Shigeo Taniuchi, Executive Officer and Presidentident of Subsidiary | ||
| Kunihito Minakawa, Independent Director | ||
| Minori Hara, Chief Officer |
Santen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Santen Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 388.22 M | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Earning | 14.22 X | |||
| Price To Book | 1.39 X | |||
| Price To Sales | 0.01 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Santen Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Santen Pharmaceutical information on this page should be used as a complementary analysis to other Santen Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Santen Pink Sheet analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |